CN102647978A - 包含溶解性差的活性成分和高支化聚合物的药物组合物 - Google Patents

包含溶解性差的活性成分和高支化聚合物的药物组合物 Download PDF

Info

Publication number
CN102647978A
CN102647978A CN2010800550800A CN201080055080A CN102647978A CN 102647978 A CN102647978 A CN 102647978A CN 2010800550800 A CN2010800550800 A CN 2010800550800A CN 201080055080 A CN201080055080 A CN 201080055080A CN 102647978 A CN102647978 A CN 102647978A
Authority
CN
China
Prior art keywords
branched polymer
hyper branched
medicine
pharmaceutical composition
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800550800A
Other languages
English (en)
Chinese (zh)
Inventor
S·雷文
E·扎加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09172391A external-priority patent/EP2311435A1/fr
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Publication of CN102647978A publication Critical patent/CN102647978A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800550800A 2009-10-07 2010-10-06 包含溶解性差的活性成分和高支化聚合物的药物组合物 Pending CN102647978A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09172391.6 2009-10-07
EP09172391A EP2311435A1 (fr) 2009-10-07 2009-10-07 Composition pharmaceutique comprenant un principe actif peu soluble et un polymère hyper-ramifié
EP10153918 2010-02-18
EP10153918.7 2010-02-18
PCT/EP2010/064916 WO2011042463A2 (fr) 2009-10-07 2010-10-06 Composition pharmaceutique comprenant un principe actif médiocrement soluble et un polymère hyper-ramifié

Publications (1)

Publication Number Publication Date
CN102647978A true CN102647978A (zh) 2012-08-22

Family

ID=43127622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800550800A Pending CN102647978A (zh) 2009-10-07 2010-10-06 包含溶解性差的活性成分和高支化聚合物的药物组合物

Country Status (3)

Country Link
EP (1) EP2485716A2 (fr)
CN (1) CN102647978A (fr)
WO (1) WO2011042463A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105613547A (zh) * 2016-03-30 2016-06-01 青岛农业大学 格列本脲在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的用途
WO2017041679A1 (fr) * 2015-09-07 2017-03-16 常州方楠医药技术有限公司 Dispersion solide de tadalafil et d'excipients pharmaceutiques, et procédé de préparation de la dispersion solide
CN112535665A (zh) * 2020-12-14 2021-03-23 宁夏医科大学 一种格列吡嗪固体分散体及制备方法和包含其的格列吡嗪固体分散体片及制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (fr) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (fr) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
WO2014003678A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil
WO2014003677A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant des particules de dispersion solide contenant du tadalafil
US9492406B2 (en) * 2012-09-20 2016-11-15 Ipca Laboratories Ltd. Pharmaceutical composition
PL3021832T3 (pl) 2013-07-19 2021-08-23 Boehringer Ingelheim Vetmedica Gmbh Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny
DK2925305T3 (en) 2013-12-04 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan.
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
US20060216265A1 (en) * 2002-07-19 2006-09-28 The Regents Of The University Of California Dendrimers as molecular translocators
CN101163463A (zh) * 2005-02-21 2008-04-16 巴斯福股份公司 包含至少一种含氮原子的超支化聚合物的活性物质组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200501260A1 (ru) 2003-02-13 2006-06-30 Нэйшнел Сентер Фо Сайнтифик Рисёч "Демокритос" Многофункциональные дендримеры и сверхразветвленные полимеры и их применение в качестве систем для доставки лекарств и генетического материала

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
US20060216265A1 (en) * 2002-07-19 2006-09-28 The Regents Of The University Of California Dendrimers as molecular translocators
CN101163463A (zh) * 2005-02-21 2008-04-16 巴斯福股份公司 包含至少一种含氮原子的超支化聚合物的活性物质组合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041679A1 (fr) * 2015-09-07 2017-03-16 常州方楠医药技术有限公司 Dispersion solide de tadalafil et d'excipients pharmaceutiques, et procédé de préparation de la dispersion solide
CN105613547A (zh) * 2016-03-30 2016-06-01 青岛农业大学 格列本脲在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的用途
CN112535665A (zh) * 2020-12-14 2021-03-23 宁夏医科大学 一种格列吡嗪固体分散体及制备方法和包含其的格列吡嗪固体分散体片及制备方法

Also Published As

Publication number Publication date
WO2011042463A2 (fr) 2011-04-14
EP2485716A2 (fr) 2012-08-15
WO2011042463A3 (fr) 2012-02-23

Similar Documents

Publication Publication Date Title
CN102647978A (zh) 包含溶解性差的活性成分和高支化聚合物的药物组合物
DiNunzio et al. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole
RU2478371C2 (ru) Способ получения композиции полимерных мицелл, содержащей лекарство, слаборастворимое в воде
JP5484910B2 (ja) レバプラザン含有の固体分散体及びその製造方法
CA2906029C (fr) Forme pharmaceutique a dispersion rapide contenant du levetiracetam
JP2007504266A (ja) ジプラシドンの持続放出剤形
CN104936589A (zh) 具有改善的生物利用度的药物组合物
US20230321246A1 (en) High-strength oral taxane compositions and methods
US20170281586A1 (en) Solid molecular dispersion of fesoterodine hydrogen fumarate and polymeric binder
CN101454003B (zh) 包含3-[5-[4-(环戊氧基)-2-羟基苯甲酰基]-2-[(3-羟基-1,2-苯并异噁唑-6-基)甲氧基]苯基]丙酸或其盐的口服组合物
Sohn et al. Design of telmisartan-weak acid solid dispersion to improve its solubility and stability
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
JP2013151574A (ja) チューブリンインヒビターであるインジブリン（Ｉｎｄｉｂｕｌｉｎ）の改良された薬物動態学を有する、経口投与のための薬剤組成物、及びその製造法
ES2663721T3 (es) Formulaciones de olmesartán
Telange et al. Development and characterization of pentaerythritol-eudragitrs100 Co-processed excipients as solid dispersion carriers for enhanced aqueous solubility, in vitro dissolution, and ex vivo permeation of atorvastatin
EP2311435A1 (fr) Composition pharmaceutique comprenant un principe actif peu soluble et un polymère hyper-ramifié
US20200078463A1 (en) Composition having improved water solubility and bioavailability
CN103860464B (zh) 一种抗过敏药物缓释混悬剂及其制备方法
WO2011154755A1 (fr) Atorvastatine nanostructurée, ses sels pharmaceutiquement acceptables et des compositions de ceux-ci, procédé pour leur préparation et compositions pharmaceutiques les contenant
Parikh et al. Formulation optimization and evaluation of immediate release tablet of telmisartan
US20220241230A1 (en) Diclofenac sachet composition
Kumar B et al. In-vitro–In-vivo Characterization of‎ Glimepiride Lipid Nanoparticulates‎ Prepared by Combined Approach of‎ Precipitation and Complexation
Maghsoodi et al. New Insight into Acidifier-Induced Enhancement of Dissolution of Weakly Basic Drug, Dipyridamole
WO2023044024A1 (fr) Nouveau système d'administration de médicament à revêtement dépendant du ph
US20200246297A1 (en) Liquid pharmaceutical formulations of tetraiodothyronine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120822